Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE735.4021.55 (+3.02 % )
PREV CLOSE (Rs.) 713.85
OPEN PRICE (Rs.) 710.00
BID PRICE (QTY) 732.80 (2000 )
OFFER PRICE (QTY) 736.00 (50 )
VOLUME 210206
TODAY'S LOW / HIGH (Rs.)710.00 750.50
52 WK LOW / HIGH (Rs.)281.15 734.8
NSE741.90 27.95 (+3.91 % )
PREV CLOSE(Rs.) 713.95
OPEN PRICE (Rs.) 715.90
BID PRICE (QTY) 741.85 (499 )
OFFER PRICE (QTY) 741.90 (172 )
VOLUME 8174693
TODAY'S LOW / HIGH(Rs.) 711.20 750.35
52 WK LOW / HIGH (Rs.)288.85 734.8

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.34
TTM EPS (Rs.) 27.44
P/E Ratio 26.92
Book Value (Rs.) 213.23
Face Value (Rs.) 1
MCap (Rs. in Mn) 432832.85
Price/Earning (TTM) 20.92
Price/Sales (TTM) 3.44
Price/Book (MRQ) 3.46
PAT Margin (%) 12.48
ROCE (%) 14.85
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
04May05-04-2020$Aurobindo Pharma gets USFDA’s nod for Flucytosine Capsules Aurobindo Pharma gets USFDAâ

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Flucytosine Capsules, 250 mg and 500 mg. Flucytosine Capsules are generic version of Bausch Health’s Ancobon Capsules. The product will be launched in June 2020. Flucytosine Capsules are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.

This is the 3rd ANDA to be approved out of APL Healthcare formulation facility in Hyderabad, India used for manufacturing oral products. The company now has a total of 429 ANDA approvals (401 Final approvals including 23 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has received final approval from the US Food a..
04May05-04-2020$Aurobindo Pharma zooms on getting USFDA’s nod for Flucytosine Capsules Aurobindo Pharma zooms on ge

Aurobindo Pharma is currently trading at Rs. 667.50, up by 41.55 points or 6.64% from its previous closing of Rs. 625.95 on the BSE.

The scrip opened at Rs. 618.85 and has touched a high and low of Rs. 681.00 and Rs. 605.05 respectively. So far 421142 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 829.90 on 02-May-2019 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 681.00 and Rs. 605.05 respectively. The current market cap of the company is Rs. 39105.54 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.60% and 13.53% respectively.

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Flucytosine Capsules, 250 mg and 500 mg. Flucytosine Capsules are generic version of Bausch Health’s Ancobon Capsules. The product will be launched in June 2020. Flucytosine Capsules are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.

This is the 3rd ANDA to be approved out of APL Healthcare formulation facility in Hyderabad, India used for manufacturing oral products. The company now has a total of 429 ANDA approvals (401 Final approvals including 23 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 667.50, up by 41.5..
29Apr04-29-2020$Aurobindo Pharma informs about compliance certificate Aurobindo Pharma informs abo

Pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Aurobindo Pharma has informed that it has enclosed the compliance certificate for the half year ended 31.03.2020.

The above information is a part of company’s filings submitted to BSE.


Pursuant to Regulation 7(3) of SEBI (Listing Obligations and Di..
22Apr04-22-2020$Aurobindo Pharma gets VAI classification from USFDA for Hyderabad unit Aurobindo Pharma gets VAI cl
The US Food and Drug Administration (USFDA) has decided that the inspection classification of Aurobindo Pharma’s injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI). As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.

The inspection of Unit IV at Hyderabad, an injectable manufacturing formulation facility of the company, was conducted between November 4-13, 2019 by the USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

The US Food and Drug Administration (USFDA) has decided that th..
22Apr04-22-2020$Aurobindo Pharma surges on getting VAI classification from USFDA for Hyderabad unit Aurobindo Pharma surges on g

Aurobindo Pharma is currently trading at Rs. 650.50, up by 6.05 points or 0.94% from its previous closing of Rs. 644.45 on the BSE.

The scrip opened at Rs. 651.00 and has touched a high and low of Rs. 684.25 and Rs. 631.75 respectively. So far 1470430 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 684.25 and Rs. 510.45 respectively. The current market cap of the company is Rs. 38159.25 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.60% and 13.53% respectively.

The US Food and Drug Administration (USFDA) has decided that the inspection classification of Aurobindo Pharma’s injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI). As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.

The inspection of Unit IV at Hyderabad, an injectable manufacturing formulation facility of the company, was conducted between November 4-13, 2019 by the USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma is currently trading at Rs. 650.50, up by 6.05..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit4190.7000000000115297.3
Gross Profit 5493.00000000001 19646.2
Operating Profit 6891.6000000000125085.7
Net Sales 33456.7122578.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 16800.00 (1.23%)
M.Cap ( in Cr)
35482.72
Dr. Reddys Lab (BSE)
 4057.95 (4.35%)
M.Cap ( in Cr)
67599.63
Astrazeneca Pharma I (BSE)
 3080.80 (5.76%)
M.Cap ( in Cr)
7392.13
Divis Lab (BSE)
 2387.50 (4.56%)
M.Cap ( in Cr)
63304.96
Sanofi India (BSE)
 7738.70 (0.82%)
M.Cap ( in Cr)
17822.02
Shareholding Pattern More
PROMOTERS 52.01 %
NON-INSTITUTION 13.16 %
MUTUAL FUNDS/UTI 11.95 %
FI/BANKS/INSURANCE 0.61 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes